The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...

DNL343 showed no significant difference in ALSFRS-R scores or secondary endpoints compared to placebo over 24 weeks. Analysts await late-2025 data on biomarkers and subgroup findings for DNL343 ...

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks Overall, DNL343 was found to be safe and ...

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $30 from $34 and keeps a Buy rating on the shares after the company ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit. Massachusetts General Hospital found neither AbbVie and ...

Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its ...

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...